BBTX insider filings

Bambusa Therapeutics, Inc. — 14 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-11-03. Screen BBTX transaction legs live →

Insider transaction summary — last 90 days

2026-08-23 to 2026-11-21, from the filings listed below: 14 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By insider — same window

Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

InsiderFilingsPurchases (P)Sales (S)Other legs
RA CAPITAL MANAGEMENT, L.P. — Director, 10% owner & RA Capital Healthcare Fund LP — Director, 10% owner & RA Capital Nexus Fund III, L.P. — Director & Kolchinsky Peter — Director, 10% owner & Shah Rajeev M. — Director, 10% owner24 legs · 2,953,820 sh · $46,639,957—6
Jeggle Helmut Wolfgang — Director, 10% owner21 leg · 375,000 sh · $6,000,000—4
Salvia Investment GmbH — 10% owner21 leg · 375,000 sh · $6,000,000—4
Xu Shanshan — See remarks, Director, 10% owner & MiNeng, Inc. — 10% owner2——8
Xu Shanshan — See remarks, Director, 10% owner1——2
DiRocco Derek — Director1———
Foerster Christian Uwe — Director1———
Ho Minh Quoc Thang — See remarks1———
Liang Howard — Director1———
Lieber Jonathan I — Chief Financial Officer1———

Recent insider filings — Bambusa Therapeutics, Inc.

FiledFormInsiderReported transactionsSource
2026-11-034RA CAPITAL MANAGEMENT, L.P. — Director, 10% owner
RA Capital Healthcare Fund LP — Director, 10% owner
RA Capital Nexus Fund III, L.P. — Director
Kolchinsky Peter — Director, 10% owner
Shah Rajeev M. — Director, 10% owner
Purchase (P): 189,909 @ $14.23 · Purchase (P): 263,911 @ $14.92 · Conversion (C): 3,144,858 · Conversion (C): 1,331,080 · Purchase (P): 2,335,109 @ $16 · Purchase (P): 164,891 @ $16 · +4 moreEDGAR
2026-11-024Salvia Investment GmbH — 10% ownerConversion (C): 4,769,701 · Purchase (P): 375,000 @ $16 · Conversion (C): 3,135,066 (derivative) @ $0 · Conversion (C): 1,473,775 (derivative) @ $0 · Conversion (C): 160,860 (derivative) @ $0EDGAR
2026-11-024Xu Shanshan — See remarks, Director, 10% owner
MiNeng, Inc. — 10% owner
Conversion (C): 16,358 · Conversion (C): 147,238 · Conversion (C): 4,155 (derivative) @ $0 · Conversion (C): 10,450 (derivative) @ $0 · Conversion (C): 1,753 (derivative) @ $0 · Conversion (C): 37,399 (derivative) @ $0 · +2 moreEDGAR
2026-11-024Jeggle Helmut Wolfgang — Director, 10% ownerConversion (C): 4,769,701 · Purchase (P): 375,000 @ $16 · Conversion (C): 3,135,066 (derivative) @ $0 · Conversion (C): 1,473,775 (derivative) @ $0 · Conversion (C): 160,860 (derivative) @ $0EDGAR
2026-11-024Xu Shanshan — See remarks, Director, 10% ownerGrant/award (A): 379,102 (derivative) @ $0 · Grant/award (A): 758,204 (derivative) @ $0EDGAR
2026-10-293Jeggle Helmut Wolfgang — Director, 10% ownerHoldings only — no transactions reportedEDGAR
2026-10-293RA CAPITAL MANAGEMENT, L.P. — Director, 10% owner
RA Capital Healthcare Fund LP — Director
RA Capital Nexus Fund III, L.P. — Director
Kolchinsky Peter — Director, 10% owner
Shah Rajeev M. — Director, 10% owner
Holdings only — no transactions reportedEDGAR
2026-10-293Salvia Investment GmbH — 10% ownerHoldings only — no transactions reportedEDGAR
2026-10-293Foerster Christian Uwe — DirectorHoldings only — no transactions reportedEDGAR
2026-10-293DiRocco Derek — DirectorHoldings only — no transactions reportedEDGAR
2026-10-293Liang Howard — DirectorHoldings only — no transactions reportedEDGAR
2026-10-293Ho Minh Quoc Thang — See remarksHoldings only — no transactions reportedEDGAR
2026-10-293Lieber Jonathan I — Chief Financial OfficerHoldings only — no transactions reportedEDGAR
2026-10-293Xu Shanshan — See remarks, Director, 10% owner
MiNeng, Inc. — 10% owner
Holdings only — no transactions reportedEDGAR

Recent 8-K events — Bambusa Therapeutics, Inc.

Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →

FiledFormItems reportedSource
2026-11-038-K5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR

Registration filings — Bambusa Therapeutics, Inc.

Securities Act registration lifecycles tracked for this issuer (live-forward since 2026-08-01), threaded by SEC file number.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=BBTX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs